Boston Research & Management Inc. reduced its position in shares of VanEck Biotech ETF (NASDAQ:BBH – Free Report) by 2.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,351 shares of the company’s stock after selling 370 shares during the period. Boston Research & Management Inc.’s holdings in VanEck Biotech ETF were worth $2,080,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Tidemark LLC acquired a new position in VanEck Biotech ETF during the fourth quarter worth approximately $34,000. Mather Group LLC. purchased a new stake in shares of VanEck Biotech ETF during the 2nd quarter valued at $46,000. Red Lighthouse Investment Management LLC acquired a new stake in shares of VanEck Biotech ETF during the 2nd quarter worth $51,000. Principal Securities Inc. purchased a new position in shares of VanEck Biotech ETF in the 4th quarter worth $66,000. Finally, Hyman Charles D acquired a new position in VanEck Biotech ETF in the second quarter valued at $202,000. 32.05% of the stock is owned by institutional investors and hedge funds.
VanEck Biotech ETF Stock Performance
Shares of NASDAQ:BBH opened at $180.78 on Friday. The business has a 50-day moving average of $178.81 and a two-hundred day moving average of $169.58. VanEck Biotech ETF has a 12 month low of $142.51 and a 12 month high of $183.64.
About VanEck Biotech ETF
The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.
See Also
- Five stocks we like better than VanEck Biotech ETF
- What is the Nikkei 225 index?
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What is the NASDAQ Stock Exchange?
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- 3 Small Caps With Big Return Potential
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Want to see what other hedge funds are holding BBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Biotech ETF (NASDAQ:BBH – Free Report).
Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
